American Pharmacy News
  • People
  • Innovation
  • Regulatory
  • Industry
  • Federal Issues
  • State Issues
  • Directory
  • People
  • Innovation
  • Regulatory
  • Industry
  • Federal Issues
  • State Issues
  • Directory
  • Home
  • »
  • Stories
  • »
  • American Pharmacy News Reports

Dupixent drug approved by FDA for atopic dermatitis treatment

American Pharmacy News Reports | Apr 14, 2017

Sanofi and Regeneron Pharmaceuticals Inc.'s Dupixent injection has been approved by the U.S. Food and Drug Administration (FDA) for use treating adults with moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with topical prescription therapies. Read More »

Initiative launched to make HBCUs smoke- and tobacco-free

American Pharmacy News Reports | Apr 14, 2017

The Truth Initiative and CVS Health Foundation have launched an initiative to combat tobacco use at historically black colleges and universities (HBCUs). Read More »

Voluntary recall of EpiPen expanded

American Pharmacy News Reports | Apr 14, 2017

The voluntary recall of select lots of EpiPen Auto-Injectors and EpiPen Jr devices has been expanded. Read More »

AFP expresses support for Trump's energy policies

American Pharmacy News Reports | Apr 14, 2017

Praising President Donald Trump’s recent executive order to redirect the previous administration’s energy regulations, a spokesman for the grassroots Americans for Prosperity (AFP) has issued a statement of support. Read More »

Sanofi and Regeneron present Phase 3 Chronos study findings

American Pharmacy News Reports | Apr 14, 2017
The Chronos study evaluated the drug Dupixent.

Sanofi and Regeneron Pharmaceuticals recently presented Phase 3 Chronos study results at the late-breaking oral abstract session of the Annual Meeting of the American Academy of Dermatology. Read More »

Alcon receives FDA approval for AcrySof intraocular lenses

Mark Iandolo | Apr 13, 2017
AcrySof is the market leader for surgeons specializing in cataracts surgeries.

Alcon, a division of Novartis, has received approval from the U.S. Food and Drug Administration for its AcrySof IQ ReSTOR +2.5 Multifocal Toric intraocular lens with ActiveFocus optical design. The product was made for patients with an astigmatism and presbyopia who want to treat them both at the same time with cataract surgery. Read More »

Genentech receives FDA approval to market Ocrevus

American Pharmacy News Reports | Apr 13, 2017
Ocrevus is now available for U.S. patients.

Genentech's Ocrevus, the only medicine capable of treating both relapsing and primary progressive forms of multiple sclerosis, has been approved by the U.S. Food and Drug Administration. Read More »

Experts argue pharmacists are first line of defense in opioid epidemic

Tabitha Fleming | Apr 12, 2017
The prevalence of opioid abuse was the topic of a recent special issue of the Journal of the American Pharmacists Association.

Pharmacists and the difficult balance they must keep between patients suffering from chronic pain and the prevalence opioid abuse was the topic of a recent special issue of the Journal of the American Pharmacists Association Read More »

McKesson offers strategies to overcome access barriers

American Pharmacy News Reports | Apr 12, 2017
The information provided to attendees will provide them with the information they need to understand patient adherence barriers.

McKesson, the platinum sponsor of CBI’s Formulary, Co-Pay and Access Summit is presenting a new approach to patient-centric behavioral coaching with the overall goal of improving adherence despite affordability and other barriers. Read More »

PCMA critical of PhRMA ad, calling it an attempt to deflect blame

American Pharmacy News Reports | Apr 12, 2017
The PCMA calls the new ad campaign a “losing strategy.

Prescription drug costs battles are far from over as PCMA calls for the drug lobby to stop deflecting blame in an effort to maintain profit margins. Read More »

Biologics to be exclusive provider of breakthrough medication

American Pharmacy News Reports | Apr 11, 2017
BAVENCIO showed that 78.6 percent of patients responded to the medication in seven weeks' time.

Biologics Inc., which is owned by McKesson Specialty Health, has been chosen as the exclusive specialty pharmacy provider for BAVENCIO (avelumab). Read More »

Daiichi Sankyo sells Pennsylvania plant to Sharp Packaging

American Pharmacy News Reports | Apr 11, 2017
Though Sharp has gained ownership of the property, it has extended employment to former employees of the plant.

Daiichi Sankyo Inc.has sold its pharmaceutical packaging plant in Bethlehem, Pennsylvania to Sharp Packaging Services, a division of UDG Healthcare. Read More »

FDA grants priority review for Bristol-Myers' Opdivo sBLA

American Pharmacy News Reports | Apr 10, 2017
This milestone illustrates Bristol-Myers Squibb’s continued efforts to evaluate the potential of Immuno-Oncology in a broad range of cancers.

The U.S. Food and Drug Administration (FDA) has granted Bristol-Myers Squibb Co. a priority review for the company’s Opdivo Biologics License Application. Read More »

Walgreens, Prime Therapeutics to form AllianceRx Walgreens Prime

American Pharmacy News Reports | Apr 10, 2017
Walgreens and Prime Therapeutics to offer mail services and specialty pharmacy services.

Walgreens and Prime Therapeutics LLC merge to offer specialty pharmacy and mail services Read More »

AbbVie's Imbruvica sNDA accepted for review by FDA

American Pharmacy News Reports | Apr 10, 2017
 Imbruvica inhibits a protein called Bruton's tyrosine kinase that is a key signaling molecule in the B-cell receptor.

AbbVie's supplemental new drug application for ibrutinib, a product for treating chronic graft vs. host disease (cGVHD) after failure of one or more lines of systemic therapy, has received FDA approval. Read More »

Daiichi Sankyo enrolls first patient in Eliminate-AF study

Mark Iandolo | Apr 10, 2017
Lixiana is designed to fight Vitamin K antagonists in patients with atrial fibrillation undergoing catheter ablation.

Daiichi Sankyo Inc. recently announced the enrollment of the first person for its Eliminate-AF study. Read More »

Bracco Imaging invests in health technology company

American Pharmacy News Reports | Apr 9, 2017
Bracco will be better able to give health care leaders and organizations higher standards of patient safety.

Bracco Imaging has invested in PHS Technologies Group to solidify Bracco's role in the industry and increase the scope of its portfolio software applications related to dose management. Read More »

FDA approves application for breast cancer drug from Pfizer

American Pharmacy News Reports | Apr 9, 2017
The approval comes after a Phase 3 study that evaluated Ibrance first-line therapy in combination with letrozole.

Pfizer Inc.'s supplemental New Drug Application (sNDA) for Ibrance, its first-in-class cyclin dependent kinase 4/6 (CDK 4/6) inhibitor, has been approved by the U.S. Food and Drug Administration. Read More »

Panacea Pharmaceuticals shares news about cancer biomarkers

American Pharmacy News Reports | Apr 9, 2017
Exosomes are said to be nanoparticles which serve as biomarkers, increasing the information about the cancer.

Panacea Pharmaceuticals Inc. presented its paper, "Improved Detection of Cancer Specific Serum Exosomal Aspartyl (Asparaginyl) beta Hydroxylase," and its findings on the company's multi-cancer HAAH exosome detection assay during the annual American Association for Cancer Research meeting in Washington, D.C. April 1-5. Read More »

Allergan uncovers potential for using Botox to treat depression

American Pharmacy News Reports | Apr 9, 2017
The women were assigned to three different groups, each of which received a 30 U Botox injection, a 50 U Botox injection, or a placebo.

Popularly known for its ability to enhance facial appearance cosmetically, Botox is now under scrutiny for its possible application for treating major depressive disorder, based on data from a study undertaken by Allergan. Read More »

  • «
  • 1
  • 2
  • ...
  • 50
  • 51
  • 52 (current)
  • 53
  • 54
  • ...
  • 168
  • 169
  • »
Trending

Scott Newman, Chairman, Pharmacists United for Truth and Transparency

Pharmacists United for Truth and Transparency: PBMs are the ‘primary driver of high drug prices in the U.S.’

Dr. Gerard Acloque, Doctor for Florida Concierge Medicine & Wellness

Doctor on Eli Lilly compounding pharmacy lawsuit: 'We are now left with very little options outside the branded medications'

Sazan Sylejmani, Owner & Pharmacy Manager of Westmont Pharmacy

Monty's Home Medical highlights benefits of tailored compounded medications

Craig Brockie, Founder & CEO of Ultimate Health Solutions

Ultimate Health Solutions founder on Patients First: 'Our healthcare system doesn't reward health'

 Jeff Harrell Board President

NCPA comments on Trump's executive order concerning drug pricing

Copyright © 2025 American Pharmacy News. All Rights Reserved.

  • About
  • Contact
  • Privacy Policy
  • Terms of Service

Alerts Sign-up